From Casetext: Smarter Legal Research

Sanofi-Aventis U.S. LLC v. Novo Nordisk Inc.

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY
Jul 10, 2017
Civil Action No. 16-9466 (MAS) (DEA) (D.N.J. Jul. 10, 2017)

Summary

dismissing NJCFA claim because the "[p]laintiff is a competitor, and does not allege a consumer-like injury."

Summary of this case from Natreon, Inc. v. Ixoreal Biomed, Inc.

Opinion

Civil Action No. 16-9466 (MAS) (DEA)

07-10-2017

Re: Sanofi-Aventis U.S. LLC v. Novo Nordisk Inc.


CHAMBERS OF MICHAEL A. SHIPP UNITED STATES DISTRICT JUDGE NOT FOR PUBLICATION

LETTER OPINION

VIA CM/ECF
All counsel of record Dear Counsel:

This matter comes before the Court on Defendant Novo Nordisk Inc.'s ("Defendant") Motion to Dismiss Count Three of Plaintiff Sanofi-Aventis U.S. LLC's ("Plaintiff") Complaint. (ECF No. 27.) Plaintiff filed opposition (ECF No. 33), and Defendant filed a reply (ECF No. 34). The Court has reviewed the parties' submissions and decides the matter without oral argument pursuant to Local Civil Rule 78.1. After careful consideration of the submissions, Defendant's Motion to Dismiss Count Three of the Complaint is GRANTED.

Count Three alleges a violation of the New Jersey Consumer Fraud Act ("NJCFA"), N.J.S.A. 56:8-1, et seq., stating that "Defendant's commercial advertising claims are causing immediate and irreparable competitive and commercial injury to [Plaintiff], to its goodwill and reputation." (Compl. ¶ 52, ECF No. 1.) In other words, Plaintiff alleges that Defendant is a competitor that has engaged in improper practices that are causing harm to Plaintiff. (Id. ¶¶ 1-2, 48-55.) Accordingly, Defendant seeks dismissal of Count Three by asserting that competitors lack standing to bring suit under the NJCFA. (Def.'s Moving Br. 4-5, ECF No. 28.)

As recognized by both parties, the Court recently addressed this precise issue in Interlink Products International, Inc. v. F&W Trading LLC, No. 15-1340, 2016 WL 1260713 (D.N.J. Mar. 31, 2016). (See Def.'s Moving Br. 4-5; Pl.'s Opp'n Br. 3, ECF No. 33). Plaintiff argues that the Court should "reconsider [its] reasoning [in the Interlink case)." (Pl.'s Opp'n Br. 3.) Plaintiff does not identify any New Jersey state court, District of New Jersey, or Third Circuit decisions issued after Interlink that support Plaintiff's position. Upon review of the parties' submissions, the Court adopts its reasoning in Interlink, for the purposes of deciding the instant Motion, that "the NJCFA is not intended to protect competitors . . . that do not suffer a consumer-like injury." Interlink, 2016 WL 1260713, at *9 (quoting Church & Dwight Co. v. SPD Swiss Precision Diagnostics, GmBH, No. 10-453, 2010 WL 5239238, at *10 (D.N.J. Dec. 16, 2010)). As Plaintiff is a competitor, and does not allege a consumer-like injury, the Court dismisses Count Three of the Complaint.

For the foregoing reasons, the Court GRANTS Defendant's Motion to Dismiss Count Three of the Complaint.

s/ Michael A. Shipp

MICHAEL A. SHIPP

UNITED STATES DISTRICT JUDGE


Summaries of

Sanofi-Aventis U.S. LLC v. Novo Nordisk Inc.

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY
Jul 10, 2017
Civil Action No. 16-9466 (MAS) (DEA) (D.N.J. Jul. 10, 2017)

dismissing NJCFA claim because the "[p]laintiff is a competitor, and does not allege a consumer-like injury."

Summary of this case from Natreon, Inc. v. Ixoreal Biomed, Inc.
Case details for

Sanofi-Aventis U.S. LLC v. Novo Nordisk Inc.

Case Details

Full title:Re: Sanofi-Aventis U.S. LLC v. Novo Nordisk Inc.

Court:UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

Date published: Jul 10, 2017

Citations

Civil Action No. 16-9466 (MAS) (DEA) (D.N.J. Jul. 10, 2017)

Citing Cases

Natreon, Inc. v. Ixoreal Biomed, Inc.

In other words, SKP has not alleged a "consumer-like injury." See Sanofi-Aventis United States, LLC v. Novo…